Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 6/2023

31.12.2022 | REVIEW ARTICLE

A novel regulator in cancer initiation and progression: long noncoding RNA SHNG9

verfasst von: Mingxing Zhao, Yang Zhang, Shen Shen

Erschienen in: Clinical and Translational Oncology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Cancer has become the most common life-threatening disease in the world. Cancers presenting with advanced stages and metastasis show poor prognosis, even with the application of radiotherapy, surgery, chemotherapy and immunotherapy. It is of great importance to explore novel, efficient biomarkers and their internal mechanisms. Recently, it has been reported that long noncoding RNAs (lncRNAs) play important roles in tumor initiation and progression, influencing downstream mRNAs by interacting with miRNAs and functioning as sponges in competing endogenous RNA (ceRNA) networks. Small nucleolar RNA host gene 9 (SNHG9) binds with miRNAs, inducing miRNA downregulation. The downregulated miRNAs enhance downstream target gene expression via ceRNA networks. Dysregulation of SNHG9 is widely observed in tumors and is associated with clinical prognosis features, which makes it a valuable target for cancer biomarkers and therapeutics. Dysregulated SNHG9 in tumor cells also functions in tumor proliferation, colony formation, migration, invasion and inhibition of apoptosis and tumor cell metabolism. This systematic review of SNHG9 in tumors provides new perspectives on cancer diagnosis and treatment.
Literatur
1.
Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7(1):376.PubMedPubMedCentralCrossRef
2.
Heintzman DR, Fisher EL, Rathmell JC. Microenvironmental influences on T cell immunity in cancer and inflammation. Cell Mol Immunol. 2022;19(3):316–26.PubMedPubMedCentralCrossRef
3.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.PubMedCrossRef
4.
Luu M, Visekruna A. Targeting metabolic rewiring might decrease spread of tumor cells: Mitochondrial tRNA modifications promote cancer metastasis. Signal Transduct Target Ther. 2022;7(1):360.PubMedPubMedCentralCrossRef
5.
Zou W. Immune regulation in the tumor microenvironment and its relevance in cancer therapy. Cell Mol Immunol. 2022;19(1):1–2.PubMedCrossRef
6.
7.
8.
9.
Xue C, Chen C, Gu X, Li L. Progress and assessment of lncRNA DGCR5 in malignant phenotype and immune infiltration of human cancers. Am J Cancer Res. 2021;11(1):1–13.PubMedPubMedCentral
10.
Xue C, Li G, Lu J, Li L. Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression. Signal Transduct Target Ther. 2021;6(1):400.PubMedPubMedCentralCrossRef
11.
Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol Rev. 2016;96(4):1297–325.PubMedCrossRef
12.
Zhu M, Ding Q, Lin Z, Chen X, Chen S, Zhu Y. New insights of epigenetics in vascular and cellular senescence. J Transl Int Med. 2021;9(4):239–48.PubMedPubMedCentralCrossRef
13.
Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13(6):612–32.PubMed
14.
Cisneros-Villanueva M, Hidalgo-Pérez L, Cedro-Tanda A, Peña-Luna M, Mancera-Rodríguez MA, Hurtado-Cordova E, et al. LINC00460 is a dual biomarker that acts as a predictor for increased prognosis in basal-like breast cancer and potentially regulates immunogenic and differentiation-related genes. Front Oncol. 2021;2021:11628027.
15.
Derrien T, Johnson R, Bussotti G, Tanzer A, Djebali S, Tilgner H, et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res. 2012;22(9):1775–89.PubMedPubMedCentralCrossRef
16.
Palazzo AF, Koonin EV. Functional long non-coding RNAs evolve from junk transcripts. Cell. 2020;183(5):1151–61.PubMedCrossRef
17.
Xue C, Chu Q, Zheng Q, Jiang S, Bao Z, Su Y, et al. Role of main RNA modifications in cancer: N(6):-methyladenosine, 5-methylcytosine, and pseudouridine. Signal Transduct Target Ther. 2022;7(1):142.PubMedPubMedCentralCrossRef
18.
Romero-Barrios N, Legascue MF, Benhamed M, Ariel F, Crespi M. Splicing regulation by long noncoding RNAs. Nucleic Acids Res. 2018;46(5):2169–84.PubMedPubMedCentralCrossRef
19.
20.
Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang S, et al. The lncRNA MACC1-AS1 promotes gastric cancer cell metabolic plasticity via AMPK/Lin28 mediated mRNA stability of MACC1. Mol Cancer. 2018;17(1):69.PubMedPubMedCentralCrossRef
21.
Maass PG, Luft FC, Bähring S. Long non-coding RNA in health and disease. J Mol Med (Berl). 2014;92(4):337–46.PubMedCrossRef
22.
23.
Nojima T, Proudfoot NJ. Mechanisms of lncRNA biogenesis as revealed by nascent transcriptomics. Nat Rev Mol Cell Biol. 2022;23(6):389–406.PubMedCrossRef
24.
Tang Y, He Y, Zhang P, Wang J, Fan C, Yang L, et al. LncRNAs regulate the cytoskeleton and related Rho/ROCK signaling in cancer metastasis. Mol Cancer. 2018;17(1):77.PubMedPubMedCentralCrossRef
25.
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, et al. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduct Target Ther. 2022;7(1):87.PubMedPubMedCentralCrossRef
26.
Zhang Y, Mao Q, Xia Q, Cheng J, Huang Z, Li Y, et al. Noncoding RNAs link metabolic reprogramming to immune microenvironment in cancers. J Hematol Oncol. 2021;14(1):169.PubMedPubMedCentralCrossRef
27.
28.
Lin C, Yang L. Long noncoding RNA in cancer: wiring signaling circuitry. Trends Cell Biol. 2018;28(4):287–301.PubMedCrossRef
29.
Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;10:637.
30.
Zimta AA, Tigu AB, Braicu C, Stefan C, Ionescu C, Berindan-Neagoe I. An emerging class of long non-coding RNA with oncogenic role arises from the snoRNA host genes. Front Oncol. 2020;10:10389.CrossRef
31.
Zhang B, Li C, Sun Z. Long non-coding RNA LINC00346, LINC00578, LINC00673, LINC00671, LINC00261, and SNHG9 are novel prognostic markers for pancreatic cancer. Am J Transl Res. 2018;10(8):2648–58.PubMedPubMedCentral
32.
Li RH, Tian T, Ge QW, He XY, Shi CY, Li JH, et al. A phosphatidic acid-binding lncRNA SNHG9 facilitates LATS1 liquid-liquid phase separation to promote oncogenic YAP signaling. Cell Res. 2021;31(10):1088–105.PubMedPubMedCentralCrossRef
33.
Lin Y, Holden V, Dhilipkannah P, Deepak J, Todd NW, Jiang F. A Non-coding RNA landscape of bronchial epitheliums of lung cancer patients. Biomedicines. 2020;8:4.CrossRef
34.
Wang L, Huang Q, Lin Q, Chen L, Shi Q. Knockdown of long non-coding RNA small nucleolar RNA host gene 9 or hexokinase 2 both suppress endometrial cancer cell proliferation and glycolysis. J Obstet Gynaecol Res. 2021;47(6):2196–203.PubMedCrossRef
35.
Wang CJ, Chao CR, Zhao WF, Liu HM, Feng JS, Cui YX. Long noncoding RNA SNHG9 facilitates growth of glioma stem-like cells via miR-326/SOX9 axis. J Gene Med. 2022;24(1): e3334.PubMedCrossRef
36.
Zhang H, Qin D, Jiang Z, Zhang J. SNHG9/miR-199a-5p/Wnt2 Axis regulates cell growth and aerobic glycolysis in glioblastoma. J Neuropathol Exp Neurol. 2019;78(10):939–48.PubMedCrossRef
37.
Kunadirek P, Pinjaroen N, Nookaew I, Tangkijvanich P, Chuaypen N. Transcriptomic analyses reveal long non-coding RNA in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Int J Mol Sci. 2022;23:14.CrossRef
38.
Li C, Hu J, Hu X, Zhao C, Mo M, Zu X, et al. LncRNA SNHG9 is a prognostic biomarker and correlated with immune infiltrates in prostate cancer. Transl Androl Urol. 2021;10(1):215–26.PubMedPubMedCentralCrossRef
39.
Chen GY, Zhang ZS, Chen Y, Li Y. Long non-coding RNA SNHG9 inhibits ovarian cancer progression by sponging microRNA-214-5p. Oncol Lett. 2021;21(2):80.PubMedCrossRef
40.
Wen D, Liu WL, Lu ZW, Cao YM, Ji QH, Wei WJ. SNHG9, a papillary thyroid cancer cell exosome-enriched lncRNA, inhibits cell autophagy and promotes cell apoptosis of normal thyroid epithelial cell Nthy-ori-3 through YBOX3/P21 pathway. Front Oncol. 2021;2021:11647034.
41.
Bai CJ, Gao T, Liu JY, Li S, Wang XY, Fan ZF. SNHG9/miR-214-5p/SOX4 feedback loop regulates osteosarcoma progression. Neoplasma. 2022;69(5):1175–84.PubMedCrossRef
42.
Ghafouri-Fard S, Taheri M. The expression profile and role of non-coding RNAs in obesity. Eur J Pharmacol. 2021;2021:892173809.
43.
Zhang H, Li J, Shao W, Shen N. LncRNA SNHG9 is downregulated in osteoarthritis and inhibits chondrocyte apoptosis by downregulating miR-34a through methylation. BMC Musculoskelet Disord. 2020;21(1):511.PubMedPubMedCentralCrossRef
44.
Sun Y, Xiao Z, Chen Y, Xu D, Chen S. Susceptibility modules and genes in hypertrophic cardiomyopathy by WGCNA and ceRNA network analysis. Front Cell Dev Biol. 2021;2021:9822465.
45.
Song Y, Li H, Ren X, Li H, Feng C. SNHG9, delivered by adipocyte-derived exosomes, alleviates inflammation and apoptosis of endothelial cells through suppressing TRADD expression. Eur J Pharmacol. 2020;2020:872172977.
46.
Chaft JE, Shyr Y, Sepesi B, Forde PM. Preoperative and postoperative systemic therapy for operable non-small-cell lung cancer. J Clin Oncol. 2022;40(6):546–55.PubMedPubMedCentralCrossRef
47.
Xu T, Ma Q, Li Y, Yu Q, Pan P, Zheng Y, et al. A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer. Signal Transduct Target Ther. 2022;7(1):354.PubMedPubMedCentralCrossRef
48.
Tian X, Wang R, Gu T, Ma F, Laster KV, Li X, et al. Costunolide is a dual inhibitor of MEK1 and AKT1/2 that overcomes osimertinib resistance in lung cancer. Mol Cancer. 2022;21(1):193.PubMedPubMedCentralCrossRef
49.
Donington J, Schumacher L, Yanagawa J. Surgical issues for operable early-stage non-small-cell lung cancer. J Clin Oncol. 2022;40(6):530–8.PubMedCrossRef
50.
Higgins KA, Puri S, Gray JE. Systemic and radiation therapy approaches for locally advanced non-small-cell lung cancer. J Clin Oncol. 2022;40(6):576–85.PubMedCrossRef
51.
Wang R, Chen C, Kang W, Meng G. SNHG9 was upregulated in NSCLC and associated with DDP-resistance and poor prognosis of NSCLC patients. Am J Transl Res. 2020;12(8):4456–66.PubMedPubMedCentral
52.
Zhao Y, Zhang W, Huo M, Wang P, Liu X, Wang Y, et al. XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancer. Signal Transduct Target Ther. 2021;6(1):357.PubMedPubMedCentralCrossRef
53.
Zhang Y, Liu X, Wang Y, Lai S, Wang Z, Yang Y, et al. The m(6): A demethylase ALKBH5-mediated upregulation of DDIT4-AS1 maintains pancreatic cancer stemness and suppresses chemosensitivity by activating the mTOR pathway. Mol Cancer. 2022;21(1):174.PubMedPubMedCentralCrossRef
54.
Nielsen SR, Strøbech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, et al. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nat Commun. 2021;12(1):3414.PubMedPubMedCentralCrossRef
55.
56.
Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2022;2022:1475.
57.
Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612:141–7.PubMedCrossRef
58.
Xue C, Zhao Y, Li G, Li L. Multi-omic analyses of the m(5): C regulator ALYREF reveal its essential roles in hepatocellular carcinoma. Front Oncol. 2021;2021:11633415.
59.
Feng SG, Bhandari R, Ya L, Zhixuan B, Qiuhui P, Jiabei Z, et al. SNHG9 promotes hepatoblastoma tumorigenesis via miR-23a-5p/Wnt3a axis. J Cancer. 2021;12(20):6031–49.PubMedPubMedCentralCrossRef
60.
Ye S, Ni Y. lncRNA SNHG9 promotes cell proliferation, migration, and invasion in human hepatocellular carcinoma cells by increasing GSTP1 methylation, as revealed by CRISPR-dCas9. Front Mol Biosci. 2021;2021:8649976.
61.
Dalerba P, Clarke MF. Cancer stem cells and tumor metastasis: first steps into uncharted territory. Cell Stem Cell. 2007;1(3):241–2.PubMedCrossRef
62.
Liguori M, Digifico E, Vacchini A, Avigni R, Colombo FS, Borroni EM, et al. The soluble glycoprotein NMB (GPNMB): produced by macrophages induces cancer stemness and metastasis via CD44 and IL-33. Cell Mol Immunol. 2021;18(3):711–22.PubMedCrossRef
63.
Gu Y, Wang Y, He L, Zhang J, Zhu X, Liu N, et al. Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling. Mol Cancer. 2021;20(1):132.PubMedPubMedCentralCrossRef
64.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.PubMedCrossRef
65.
Wang D, Cao X, Han Y, Yu D. LncRNA SNHG9 is downregulated in non-small cell lung cancer and suppressed miR-21 through methylation to promote cell proliferation. Cancer Manag Res. 2020;2020:1279418.
66.
Erdos E, Divoux A, Sandor K, Halasz L, Smith SR, Osborne TF. Unique role for lncRNA HOTAIR in defining depot-specific gene expression patterns in human adipose-derived stem cells. Genes Dev. 2022;36(9–10):566–81.PubMedPubMedCentralCrossRef
67.
Peng S, Gao Y, Shi S, Zhao D, Cao H, Fu T, et al. LncRNA-AK137033 inhibits the osteogenic potential of adipose-derived stem cells in diabetic osteoporosis by regulating Wnt signaling pathway via DNA methylation. Cell Prolif. 2022;55(1): e13174.PubMedCrossRef
68.
Shao X, Qin J, Wan C, Cheng J, Wang L, Ai G, et al. ADSC exosomes mediate lncRNA-MIAT alleviation of endometrial fibrosis by regulating miR-150-5p. Front Genet. 2021;2021:12679643.
69.
Ren S, Xiong H, Chen J, Yang X, Liu Y, Guo J, et al. The whole profiling and competing endogenous RNA network analyses of noncoding RNAs in adipose-derived stem cells from diabetic, old, and young patients. Stem Cell Res Ther. 2021;12(1):313.PubMedPubMedCentralCrossRef
70.
Chen K, Xie S, Jin W. Crucial lncRNAs associated with adipocyte differentiation from human adipose-derived stem cells based on co-expression and ceRNA network analyses. PeerJ. 2019;7:7544.CrossRef
71.
Wang S, Zhang Y, Cai Q, Ma M, Jin LY, Weng M, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression. Mol Cancer. 2019;18(1):145.PubMedPubMedCentralCrossRef
72.
Shen S, Yao T, Xu Y, Zhang D, Fan S, Ma J. CircECE1 activates energy metabolism in osteosarcoma by stabilizing c-Myc. Mol Cancer. 2020;19(1):151.PubMedPubMedCentralCrossRef
73.
74.
Li M, Hao B, Zhang M, Reiter RJ, Lin S, Zheng T, et al. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. Signal Transduct Target Ther. 2021;6(1):330.PubMedPubMedCentralCrossRef
75.
Khan F, Khan H, Khan A, Yamasaki M, Moustaid-Moussa N, Al-Harrasi A, et al. Autophagy in adipogenesis: molecular mechanisms and regulation by bioactive compounds. Biomed Pharmacother. 2022;2022:155113715.
76.
Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T. Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2022;21(1):179.PubMedPubMedCentralCrossRef
77.
Tu Z, Karnoub AE. Mesenchymal stem/stromal cells in breast cancer development and management. Semin Cancer Biol. 2022;86(Pt 2):81–92.PubMedCrossRef
Metadaten
Titel
A novel regulator in cancer initiation and progression: long noncoding RNA SHNG9
verfasst von
Mingxing Zhao
Yang Zhang
Shen Shen
Publikationsdatum
31.12.2022
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 6/2023
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-022-03060-x

Weitere Artikel der Ausgabe 6/2023

Clinical and Translational Oncology 6/2023 Zur Ausgabe

RESEARCH ARTICLE

Frequently mutated genes in predicting the relapse of stage I lung adenocarcinoma

RESEARCH ARTICLE

HIF-1α contributes to metastasis in choriocarcinoma by regulating DEC1 expression

REVIEW ARTICLE

Histone methylation in pre-cancerous liver diseases and hepatocellular carcinoma: recent overview

RESEARCH ARTICLE

Genetic architecture of mammographic density as a risk factor for breast cancer: a systematic review

RESEARCH ARTICLE

Cancer-associated fibroblasts contribute to cancer metastasis and apoptosis resistance in human ovarian cancer via paracrine SDF-1α

RESEARCH ARTICLE

Prediction model of colorectal cancer (CRC) lymph node metastasis based on intestinal bacteria

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise